Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup?

C A Davie, N C Silver, G J Barker, P S Tofts, A J Thompson, W I McDonald, D H Miller

Abstract

Objective—To determine non-invasively the relation between the degree of axonal loss and the extent of demyelination in chronic lesions visible on MRI in patients with different subgroups of clinically definite multiple sclerosis using 1H magnetic resonance spectroscopy (1H MRS) and magnetisation transfer imaging (MT). Conventional MRI is unable to differentiate between the various pathological processes occurring in the multiple sclerosis lesion. There are, however, newer MR techniques which show promise in this respect.

Methods—1H MRS and MT were performed in 18 patients with clinically definite multiple sclerosis who had a wide range of disability and disease duration.

Results—A significant correlation was found between a reduction in the concentration of N-acetyl aspartate (NAA; an in vivo marker of axonal loss or dysfunction) and a reduction in MT ratio (a probable marker of demyelination) in patients who had entered the secondary progressive stage of the disease. Patients with minimal disability after a disease duration of greater than 10 years—so called benign multiple sclerosis—showed a relative preservation of NAA and MT.

Conclusions—Because a reduction in MT seems to be a relative marker for demyelination and a reduction of NAA from chronic lesions is indicative of axonal loss, this study supports the hypothesis that demyelination and axonal loss occur in the same chronic multiple sclerosis lesions. In addition, the degree of axonal loss and demyelination correlates with clinical heterogeneity.

Keywords: magnetisation transfer; 1H magnetic resonance spectroscopy; N-acetyl aspartate; multiple sclerosis

Although conventional MRI is sensitive in detecting the lesions of multiple sclerosis, it is not able to show changes that are specific for individual pathological processes such as demyelination or axonal loss.1 Proton magnetic resonance spectroscopy (MRS) is a nuclear magnetic resonance technique which has the potential to detect axonal loss non-invasively during life. The normal proton spectrum is dominated by N-acetyl derived groups (NA) (the sum of N-acetyl aspartate and N-acetylaspartylglutamate). The predominant component of the NA peak is N-acetyl aspartate (NAA),8 an amino acid of unknown function, which has been shown in experimental studies on primary cell cultures from neonatal rat brains and optic nerves to be contained almost exclusively within neurons.3 Although NAA is also present in oligodendrocyte progenitor (O2A) cells, these are only present in very small numbers in healthy adult human brain1 and are thus unlikely to contribute significantly to the concentration of NAA. A loss of neurons (cell bodies and axons) would thus be predicted to cause a persistent reduction in the concentration of NAA. Such a reduction has been reproducibly demonstrated in several diseases characterised by neuronal loss.5,7 There is now an extensive literature showing a reduction of NAA from acute lesions (where it may be partly reversible, suggesting axonal dysfunction rather than loss),6,7 chronic multiple sclerosis lesions,7 and from areas of normal appearing white matter.8–10 Furthermore, the degree of NAA reduction (and therefore axonal loss) seems to be most marked in those patient groups with greatest neurological disability.10 12 13 14 15 16 17 18 19 20 21 22 23 H MRS is also able to detect myelin breakdown products after acute demyelination.24 25 These products resolve over time26 and it is not yet possible with this technique to gauge the degree of demyelination that has occurred nor indeed the extent of remyelination.

The technique of MT is a nuclear magnetic resonance technique which relies on the transfer of energy between highly bound protons within structures such as myelin and the very mobile protons of free water.27 This effect can be quantified as an MT ratio—and shows promise in being able to differentiate between the MRI changes of demyelination22 23 from that of oedema.22 Dousset et al22 were able to show a modest reduction of the MT ratio from brain lesions in guinea pigs after the induction of experimental allergic encephalomyelitis (a condition in which there is inflammation and oedema in the absence of demyelination). By contrast, a significant reduction in the MTR was seen from lesions in patients with multiple sclerosis. Gass et al28 have shown that the degree of MT ratio reduction in patients with multiple sclerosis correlates with clinical disability indicating that a low MT ratio is indicative of a more destructive pathological process. It has been proposed therefore that MT imag-
Axonal loss and demyelination from chronic lesions in multiple sclerosis and clinical subgroup

Table 1 Clinical and MR data of all patients with multiple sclerosis

<table>
<thead>
<tr>
<th>Patient</th>
<th>Disease duration (y)</th>
<th>Clinical group</th>
<th>EDS</th>
<th>(NAA) lesion</th>
<th>MT ratio lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7</td>
<td>2 y progressive</td>
<td>5.5</td>
<td>3.5 mM</td>
<td>14.6</td>
</tr>
<tr>
<td>2</td>
<td>20</td>
<td>2 y progressive</td>
<td>7.5</td>
<td>9.97 mM</td>
<td>23.6</td>
</tr>
<tr>
<td>3</td>
<td>7</td>
<td>2 y progressive</td>
<td>4.5</td>
<td>8.47 mM</td>
<td>23.3</td>
</tr>
<tr>
<td>4</td>
<td>13</td>
<td>2 y progressive</td>
<td>8.0</td>
<td>5.4 mM</td>
<td>18.9</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>2 y progressive</td>
<td>7.5</td>
<td>8.2 mM</td>
<td>25.2</td>
</tr>
<tr>
<td>6</td>
<td>7</td>
<td>2 y progressive</td>
<td>7.5</td>
<td>10.07 mM</td>
<td>21.8</td>
</tr>
<tr>
<td>7</td>
<td>14</td>
<td>2 y progressive</td>
<td>4.0</td>
<td>10.3 mM</td>
<td>28.6</td>
</tr>
<tr>
<td>8</td>
<td>20</td>
<td>Benign</td>
<td>3.0</td>
<td>11.45 mM</td>
<td>25.4</td>
</tr>
<tr>
<td>9</td>
<td>15</td>
<td>Benign</td>
<td>2.5</td>
<td>8.53 mM</td>
<td>27.2</td>
</tr>
<tr>
<td>10</td>
<td>14</td>
<td>Benign</td>
<td>2.0</td>
<td>9.01 mM</td>
<td>28.2</td>
</tr>
<tr>
<td>11</td>
<td>19</td>
<td>Benign</td>
<td>2.0</td>
<td>12.8 mM</td>
<td>28.1</td>
</tr>
<tr>
<td>12</td>
<td>25</td>
<td>Benign</td>
<td>2.5</td>
<td>9.9 mM</td>
<td>27.6</td>
</tr>
<tr>
<td>13</td>
<td>5</td>
<td>Relapsing-remitting</td>
<td>2.5</td>
<td>10.14 mM</td>
<td>20.9</td>
</tr>
<tr>
<td>14</td>
<td>4</td>
<td>Relapsing-remitting</td>
<td>5.0</td>
<td>9.67 mM</td>
<td>24.2</td>
</tr>
<tr>
<td>15</td>
<td>2</td>
<td>Relapsing-remitting</td>
<td>2.0</td>
<td>10.66</td>
<td>27.9</td>
</tr>
<tr>
<td>16</td>
<td>3</td>
<td>1 y progressive</td>
<td>6.0</td>
<td>9.02 mM</td>
<td>28.0</td>
</tr>
<tr>
<td>17</td>
<td>4</td>
<td>1 y progressive</td>
<td>5.0</td>
<td>9.84 mM</td>
<td>27.3</td>
</tr>
<tr>
<td>18</td>
<td>3</td>
<td>1 y progressive</td>
<td>6.0</td>
<td>9.05 mM</td>
<td>23.8</td>
</tr>
<tr>
<td>Median control values</td>
<td></td>
<td></td>
<td></td>
<td>12.3 mM</td>
<td>31.3</td>
</tr>
</tbody>
</table>

Patients and methods

Magnetic resonance imaging, MT imaging, and MRS were carried out in 18 patients with clinically definite multiple sclerosis. This group comprised patients with a wide range of disability (range 2.0–8.0, median 5.0) and disease duration (range 2–25 years, median 7 years, table).

Magnetic resonance imaging, MRS, and MT were performed with a 1.5 T GE signa whole body scanner using a standard quadrature head coil. The study commenced with a T2 weighted fast spin echo imaging sequence (TR 5000 ms, TE 80 ms) (5 mm slices with 2.5 mm gap, 256×256 matrix, echo train length 8). After imaging, a volume of interest localised to a periventricular white matter lesion was prescribed ranging in size from 3.5 to 5 ml. The size and shape of each volume was adjusted to minimise partial volume effects. Lesions were chosen which had not altered on conventional MRI for 12 months or more and which were large enough to fill 70% or greater of the spectroscopic volume.

An MRI of the voxel was then obtained to ensure accurate localisation. Water suppressed 1H spectra were obtained using a STEAM sequence. As a pathological control we have also studied the brainstem from one patient with a clinical diagnosis of central pontine myelinolysis—a disorder which is characterised pathologically by demyelination in the absence of axonal loss.

A comparative study using MRS and MT was performed in chronic lesions to assess (1) whether axonal loss and demyelination occur together in the same lesions and (2) to determine the relation between the degree of axonal loss and demyelination and clinical heterogeneity.

As a pathological control we have also carried out MT and 1H MRS in a patient with central pontine myelinolysis—a disorder which is characterised pathologically by demyelination in the absence of axonal loss.

Statistical analysis was performed with a Mann-Whitney confidence interval and test. Results are expressed as a median value together with the range and p value. A Spearman’s rank correlation test was also used and results are expressed as an r value together with levels of significance.

**Magnetisation transfer**

Magnetisation transfer images were obtained from the same lesions and areas of normal appearing white matter (NAWM) studied by spectroscopy in the patients with multiple sclerosis and in eight healthy age matched controls. Eight axial slices through the the hemispheres were obtained which covered the regions of brain from which MRS had been performed.
Dual spin echo images were obtained (spin echo = 1,500/32/80, eight slices, 5 mm thickness, 2.5 mm gap, 256 × 128 matrix, scan time = 10 min), with and without the application of a saturation prepulse to saturate the broad resonance of immobile macromolecular protons. The applied pulse was a four lobed, 64 ms sinc pulse, 2 kHz off water resonance. The energy deposited by this pulse ensured a good signal to noise in the calculated MT image. To ensure exact coregistration of the saturated and unsaturated images, scans with and without saturation were interleaved for each phase encoding step. From the two images—that is, without (Mo) and with (Ms) saturation pulse—quantitative MT ratio images were derived pixel by pixel according to the equation:

\[
\text{MT ratio} = \left( \frac{\text{Mo} - \text{Ms}}{\text{Mo}} \right) \times 100\% \text{ units (pu)}
\]

Signal intensities in the calculated image represented the amount of MT between the free and bound water pool.\(^2\)\(^1\)\(^2\)\(^1\)

Magnetisation transfer ratios were calculated on the proton density images from a volume corresponding to the spectroscopic volumes of lesions and NAWM described above.

Statistical analysis was performed with a Mann-Whitney confidence interval and test. Results are expressed as a median value together with the range and \(p\) value.

**Results**

There was a significant reduction of NAA and MT ratio value from the chronic multiple sclerosis lesions compared with the control group (median NAA 12.3 mM, range 10.77 mA–13.7 mM).

There was a significant correlation between a reduction in the absolute concentration of NAA from the chronic multiple sclerosis lesions (median 9.25 mM, range 3.5 mM–12.8 mM) visible on MRI and a reduction in the MTR (median 25.3 u, range 14.6–28.6 u) from the same lesion (\(p<0.002, r=0.71, \text{fig 1}\)).

**Patients with Secondary Progressive Multiple Sclerosis**

The patients with secondary progressive multiple sclerosis (\(n=7\)) showed a particularly strong correlation between concentration of NAA (median 8.47 mM, range 3.5 mM–10.3 M) and MT ratio (median 23.3 pu, range 14.6–28.6 pu) (\(r=0.833, p<0.05, \text{fig 2}\)).

**Patients with Benign Multiple Sclerosis**

The patients with benign multiple sclerosis (\(n=5\)) showed no significant correlation between concentration of NAA (median 9.9 mM, range 8.53 mM–12.8 mM) and the MT ratio (median 27.2 pu, range 25.4–28.2) (\(r=-0.16, p>0.5\), fig 3).

**Central Pontine Myelonolysis**

\(^1\)H MRS and MT was also performed in a patient with a clinical diagnosis of central pontine myelonolysis. A coronal T1 weighted image (fig 4) showed marked hypointensity in the pons. There was marked reduction of the MT ratio in the pons (mean lesion ratio, 14.8, range

---

**Figure 1** Scattergraph of concentration of NAA from chronic lesions visible on T2 weighted MRI from parietal white matter in all patients with multiple sclerosis (\(n=18\)) correlated against a reduction in the MT ratio (MTR) from the same lesions.

**Figure 2** Scattergraph of concentration of NAA from chronic lesions visible on T2 weighted MRI from parietal white matter in patients with secondary progressive multiple sclerosis (\(n=7\)) correlated against a reduction in the MT ratio (MTR) from the same lesions.

**Figure 3** Scattergraph of concentration of NAA from chronic lesions visible on T2 weighted MRI from parietal white matter in patients with benign multiple sclerosis (\(n=5\)) correlated against a reduction in the MTR (MTR) from the same lesions.
5.9–29.5 pu) compared with five age matched controls (mean 38.9 pu). However, there was preservation of the NAA/creatine ratio from the pons (fig 4) at 2.1 compared with five age matched controls (mean NAA/creatine 2.0, range 1.5–2.9) indicating axonal preservation in the patient with central pontine myelinolysis. It was not possible to calculate the absolute concentration of NAA from the pons in this patient because of insufficient information about relaxation parameters in this region of the brain.

Discussion

The most important finding in this study is the strong correlation between a reduction in the absolute concentration of NAA and reduction in the MT ratio in chronic multiple sclerosis lesions from patients with secondary progressive multiple sclerosis. Furthermore, chronic lesions in patients with benign disease showed a relative preservation of NAA and MT ratio. These observations are contrasted with the findings in a known pure demyelinating lesion of central pontine myelinolysis in which the MT ratio was reduced and NAA/creatine ratio preserved.

A previous study by Hiehle et al has looked at the correlation of 3H MRS and magnetisation transfer in multiple sclerosis lesions and normal appearing white matter in multiple sclerosis. This was a study in 11 patients with clinically definite multiple sclerosis, nine of whom had relapsing-remitting disease, one had progressive multiple sclerosis, and one had benign disease. The authors failed to show a correlation between relative concentrations of NAA/creatine and MT ratio from multiple sclerosis lesions. This is perhaps not surprising given the results of the current study which show that the most marked correlation between a reduction in NAA and a reduced MT ratio occurs in patients with progressive disease. The positive correlation between MT ratio and NAA in patients with secondary progressive but not benign disease in the present study may indicate that the clinical pattern of disease in longstanding multiple sclerosis is a consequence of pathological heterogeneity within brain lesions.

The study by Hiehle et al did show a significant correlation between the presence of so called “marker peaks” between 2.1 and 2.6 ppm in the spectrum and a fall in the MT ratio. The authors speculated that the increased signal between 2.1 and 2.6 ppm represented myelin breakdown products and that a marked reduction in MT ratio was thus a specific marker for demyelination. In a more recent study the same group have shown a positive correlation between a reduction in the NAA/Cr ratio and MT ratio value in focal high signal lesions visible on MR. The patients in this study were not subdivided on the basis of...
their clinical picture; therefore, it is unclear whether this correlation was predominantly in those patients with fixed neurological deficit. A recent study from our own group17 has shown that it is possible to demonstrate a reduction in the MT ratio in acute gadolinium enhancing lesions followed by a marked recovery of the MT ratio over time (though not quite back to control values). Although it is possible to hypothesise various mechanisms for this observation, one possibility is that an acute reduction of the MT ratio occurs as a consequence of demyelination. The partial resolution of MT ratio found in some lesions may represent remyelination, which we know from pathological studies can be extensive.18

The patients with benign multiple sclerosis showed a relative preservation of NA and MT ratio. This suggests axonal preservation within these lesions. The preserved MT ratio suggests that these lesions have never been demyelinating or perhaps more likely that they have preserved the mechanisms which allow them the capacity to remyelinate.

The results of the current study support the hypothesis that there is a failure of remyelination in the chronic lesions of patients with secondary progressive multiple sclerosis. There are various factors which may prevent remyelination. Firstly, gliosis is a prominent feature of the chronic multiple sclerosis lesion. Excessive production of glial cells may impede the migration of oligodendrocyte precursors to areas of demyelination. Secondly, remyelination may be prevented by the death of oligodendrocyte precursor cells. Finally, the ability of a lesion to remyelinate is of course dependent on the physical integrity of axons. If axonal loss is a prominent feature within a lesion then the potential to remyelinate will be limited. Although axonal loss may occur within acute lesions it occurs to a far greater extent in chronic plaques. This final mechanism is supported by our finding of a reduced MT ratio in those lesions with greatest axonal loss as evidenced by a reduction in concentrations of NA.

The current study then supports the hypothesis that demyelination and axonal loss occur within the same lesions. This does not necessarily mean that there is a single causative factor for both pathologies. However it does seem likely that the potential for remyelination to occur within a lesion is dependent on the degree of axonal loss or dysfunction that has also occurred. The degree of remyelination is also likely to be influenced by other factors such as the development of gliosis, which is also known to be far more prominent within the chronic lesion. As yet there are no specific nuclear magnetic resonance markers to quantify the degree of gliosis that occurs in and around a multiple sclerosis lesion. It is also uncertain to what extent gliosis contributes to the MT effect.

In this study we were also also able to perform MT and 1H MRS in a patient with central pontine myelinolysis. This is an acute neurological condition characterised pathologically by demyelination in the absence of inflammation or axonal loss. This condition therefore represents an example of a relatively “pure” demyelinating model. The finding of a marked reduction in the MT ratio with only a relatively small decrease in NAA (an axonal marker) from an acute lesion is further evidence that MT can be used as a non-invasive marker for demyelination. This hypothesis is also supported by several other lines of evidence. Firstly, a reduction of MT has been found in models of experimental allergic encephalomyelitis, in which there was demyelination and preservation of axons.19 Secondly, a study by Thorpe et al20 has shown an inverse correlation between the MT ratio in symptomatic optic nerve lesions and the latency of the visual evoked potential suggesting a linear relation between MT ratio and the extent of demyelination. As mentioned earlier Lai et al37 have shown partial reversibility in the reduction of the MT ratio which occurs in the evolution of the acute gadolinium enhancing multiple sclerosis lesion. The recovery of the MT ratio in acute lesions (in which there is relative axonal preservation) implies that MT provides a more specific index of demyelination.

One confounding factor in the interpretation of a reduction in the MT ratio in a chronic multiple sclerosis lesion is that it is probably not specific for demyelination. A pathological study by Lexa et al36 in a feline model after sectioning has shown continuing reduction in the MT ratio over time, which corresponded well with the histological phases of Wallerian degeneration. It therefore remains unclear to what extent axonal loss contributes to the persistent reduction of MT ratio in a chronic multiple sclerosis lesion. This problem is difficult to disentangle in human studies as a loss of axons will invariably be associated with myelin loss. The very low MT ratio occurring in the central pontine myelinolysis lesion (in which no axonal loss occurred) would suggest that myelin provides the principal component to the MT ratio. The combined use of NAA and MT ratio still seems a promising means of increasing pathological specificity, as MT ratio can be used as a marker of demyelination whereas a persistent reduction in NAA will determine the degree of axon loss. Their serial application in the earlier stages of multiple sclerosis may help elucidate the temporal profile of myelin and axonal damage.

This study then supports the hypothesis that demyelination and axonal loss occur in the same chronic multiple sclerosis lesions. However to confirm this, a study with pathological correlation is necessary to determine the absolute pathological specificity of 1H MRS and MT.

Axonal loss and demyelination from chronic lesions in multiple sclerosis and clinical subgroup


Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup?
C A Davie, N C Silver, G J Barker, P S Tofts, A J Thompson, W I McDonald and D H Miller

J Neurol Neurosurg Psychiatry 1999 67: 710-715
doi: 10.1136/jnnp.67.6.710

Updated information and services can be found at:
http://jnnp.bmj.com/content/67/6/710

These include:

References
This article cites 37 articles, 15 of which you can access for free at:
http://jnnp.bmj.com/content/67/6/710#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (1943)
- Multiple sclerosis (934)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/